Merck Lung Cancer Innovation Challenge Launch Event Recording
Of the four most common cancers, lung cancer, has the lowest survival rate, regardless of stage at diagnosis. The five-year relative survival ratio is 60.8 percent when diagnosed at Stage 1, and only 3.3 percent when diagnosed at Stage 4. It is estimated that 29,800 new lung cancer cases will be diagnosed in 2020 across Canada, with almost 40 percent of those cases residing in Ontario alone.
On January 20, 2021, MaRS and Merck Canada launched the Lung Cancer Innovation Challenge. The competition asks Ontario-based innovators to identify, implement and scale solutions that can enhance a lung cancer patient's journey by seeking to reduce the length of time between diagnosis and treatment for lung cancer patients, and enable improved treatment outcomes.
Finalists will receive up to $100,000 for their submission with the potential for additional funding to scale their solution across Ontario.
The challenge’s virtual launch featured a panel discussion on the barriers and opportunities associated with the diagnosis and treatment of lung cancer, with a diverse range of perspectives including: Dr. Olexiy Aseyev, Medical Oncologist, Thunder Bay Regional Health Sciences Centre Bill Mantel, former Assistant Deputy Minister of the Ontario Ministry of Research and Innovation; lung cancer patient Andrea Redway, lung cancer patient Jessica Sopher, Manager of Policy and Government Relations at Lung Health Foundation Dr. Paul Wheatley-Price, President of Lung Cancer Canada